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Introduction: There is a paucity of data on the occurrence of congenital toxoplasmosis in
children  born to mothers dually infected with HIV and Toxoplasma gondii.
Objective:  To evaluate aspects of the mother–infant pairs associated with vertical transmis-
sion  of toxoplasmosis in women co-infected with HIV in a referral center for perinatally
acquired  infections in Belo Horizonte, Brazil.
Methods: Descriptive study of HIV vertically exposed children, with congenital toxoplasmo-
sis,  followed at a referral center (cohort/Belo Horizonte). Prenatal and post-natal variables for
the mother–infant pairs were evaluated. A literature review with no ﬁltering for time and
language  was performed to identify reports of congenital toxoplasmosis in HIV vertically
exposed  children.
Results:  Among 2007 HIV vertically exposed children evaluated in the period from 1998 to
2011,  10 cases of congenital toxoplasmosis were identiﬁed (incidence: 0.5%, 95% conﬁdence
interval:  0.24–0.91). In searching the literature 22 additional cases in 17 reports were found.
Combining  the ﬁndings of our cohort with other reported cases, 50% (16/32) of congenital
toxoplasmosis  in HIV vertically exposed children were from Brazil. The cases of congenital
toxoplasmosis  in HIV vertically exposed children identiﬁed in Brazil occurred mainly in thepost-Highly  Active Antiretroviral Therapy era (p = 0.002) and presented a lower death rate
(p  = 0.003) than those from other countries. In the cohort/Belo Horizonte, HIV infection was
identiﬁed  mainly during gestation; T. gondii vertical transmission was  observed in pregnant
women  with CD4+ > 500 cells/mm3 and latent toxoplasmosis. High rates of ocular lesions
(87.5%)  and central nervous system involvement (70%) were detected.
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Conclusions: The risk of vertical transmission of T. gondii in HIV-infected women is low and
has been usually associated with maternal immunosuppression and elevated viral load.
However, our ﬁndings of congenital toxoplasmosis in children born to HIV-infected moth-
ers with latent toxoplasmosis and not immunosuppressed emphasize the need for careful
follow-up in these cases.
© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Toxoplasma gondii infection has a worldwide occurrence,
higher prevalence in tropical countries and is associated with
weather  conditions, cat population, and local life habits.1 Clas-
sical  descriptions include three strains of the parasite: type
1  is usually associated with acute infection; type II is pre-
dominant in immunosuppressed individuals and in human
congenital and eye infections; and type III is frequently iso-
lated  in animals.2 In Brazil, genetic diversity is greater than
that  in most other countries, and recombinant and atypical
genotypes are predominant, usually associated with higher
virulence.3–5
The prevalence of toxoplasmosis among pregnant women
in  Brazil range from 50% to 80%.6 In the metropolitan area of
Belo  Horizonte, state of Minas Gerais, where the current study
was  carried out, the seroprevalence is estimated in 60%.6 The
prevalence  of congenital infection is rare in the USA (approx-
imately  0.01%) and higher in some Southern countries of
Western  Europe (0.01–0.1%).1,7 In Brazil, the prevalence is high
throughout  the country (0.05–0.15%), particularly in Minas
Gerais  state where it reaches 0.13%.8
In HIV-infected patients, most cases of toxoplasmosis
result from the reactivation of a latent infection.9 In immuno-
compromised pregnant women with chronic toxoplasmosis,
congenital transmission of the parasite probably occurs due to
reactivation, with chronic and intermittent parasitemia.10–13
Diagnosis in these cases is a challenge, as they are usually
associated with low IgG concentration and absence of IgM. For
this reason, the protocol proposed by Lebech et al.,14 which is
usually  used to diagnose the parasite in the mother–infant
pair, does not apply to immunosuppressed pregnant women.
The  factors determining the various clinical manifesta-
tions of congenital toxoplasmosis are still poorly known. In
fact,  there may  be a combination of factors, such as the
host’s  genotype and immune status, the parasite tissue load,
stage  of placental development, and the parasite’s own genetic
composition.15–17 In immunosuppressed children co-infected
with  HIV and T. gondii, neurological damage is mainly a result
of  the toxoplasmosis congenital infection.18
Given the high prevalence of toxoplasmosis and the pres-
ence  of more  virulent strains of the parasite in Minas Gerais,
the  difﬁculty of diagnosing a new infection or reactivation
in  immunosuppressed pregnant women, and the paucity of
studies  on congenital toxoplasmosis among children of co-
infected  mothers, this paper reports a review of the literature
and  case studies of children with congenital toxoplasmosis
that were  born to HIV and T. gondii co-infected mothers. Thesechildren have been seen at a leading outpatient referral center
in  Belo Horizonte.
Materials  and  methods
The study was  divided into two parts: a descriptive study of
congenital  toxoplasmosis in a series of cases in a historical
cohort of children vertically exposed to HIV and literature
review on congenital toxoplasmosis in infants born to HIV-
infected  mothers.
Children included in the ﬁrst part had been in follow-
up  at the Pediatric Immunology Center, Clinics Hospital,
Federal University of Minas Gerais (UFMG), over the last
22  years (1998–2011). All mother–infant pairs are users of
the  public Brazilian uniﬁed health system (SUS) in the
Metropolitan Region of Belo Horizonte and other munici-
palities in the State of Minas Gerais (Southeastern Brazil).
The  study included all children enrolled in the service that
were  born to HIV and T. gondii co-infected mothers, regard-
less  of the infection stage. The criteria used to diagnose HIV
infection  and toxoplasmosis in the mothers are described
below.
1.  HIV infection – positive for anti-HIV-1 and anti-HIV-2 in a
screening  test and in at least one conﬁrmatory test. This
included  recommendations by the Centers for Disease Con-
trol  and Prevention (CDC) and by the Brazilian Ministry of
Health.19
2. T. gondii infection – positive anti-T. gondii IgG whether or
not  associated with positive anti-T. gondii using enzyme
linked immunosorbent assay and indirect immunoﬂuores-
cence as detection methods. Determining the most likely
moment  of maternal infection involved: (a) acute infec-
tion  – pregnant women with seroconversion: maternal IgG-
and  IgM-speciﬁc serologic tests with negative ﬁrst results
and  positive second results; (b) undetermined, but probably
recent,  acute infection in the mothers: positive results for
IgG-  and IgM-speciﬁc serologic tests associated with low
IgG  avidity; and (c) chronic infection: mothers’ seroposi-
tive sample before conception or ﬁrst serologic test carried
out  during pregnancy with positive IgG and negative IgM
results  or positive IgG and IgM results, both associated with
high-avidity IgG antibodies.14The diagnosis of congenital toxoplasmosis and HIV infec-
tion  in children was  performed according to the criteria
described below.
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. HIV infection: according to recommendations by the Cen-
ters  for Disease Control and Prevention (CDC) and by the
Brazilian  Ministry of Health.19
. Congenital infection with T. gondii: according to criteria
developed by Lebech et al.14 Present IgM and/or IgA anti-T.
gondii  in the ﬁrst six months of life, persistently positive IgG
anti-T.  gondii at age of 12 months, or positive IgG associated
with  positive signs/symptoms and maternal seroconver-
sion during pregnancy. Infection was  ruled out in children
with  negative results for IgG tests in the ﬁrst year of life,
in  the absence of anti-parasite treatment, or negative IgG
after  1–3 months upon interrupting treatment in the ﬁrst
year  of life.14
The study included all children born to HIV and T. gondii co-
nfected  mothers who  fulﬁlled the criteria for the diagnosis of
ongenital  toxoplasmosis, regardless of their HIV status.
Women  were  considered immunosuppressed if CD4+ T
ymphocyte were  <350 cells/mm3, and with severe immuno-
uppression if CD4+ < 200 cells/mm3.19
In addition to the case studies, an extensive literature
eview was  carried out on Pubmed, Scielo, and Cochrane
ibrary databases. It included materials published until Jan-
ary  2012 and was  not ﬁltered for language and time period.
he  following descriptors were used: pregnancy AND toxoplas-
osis  AND HIV; congenital toxoplasmosis AND HIV; toxoplasmosis
ND  HIV.
Both the case studies and literature review targeted the
ariables related to the pregnant women (prenatal exams,
ymptomatology, immunosuppression level, and treatment)
nd  to the children (birth conditions, diagnostic methods,
ymptomatology; anti-parasitic treatment, and case out-
ome).  Information on the study participants was collected
sing  structured questionnaires to capture information from
he  clinical charts. SPSS (Statistical Package for Social Sci-
nces)  version 17.0 was  used to store and analyze the database.
escription of the clinical and laboratory variables included
bsolute  and relative frequency distribution, medians, and
ercentiles.  For comparisons between proportions Fisher’s
xact  test for small sample population was  used. Medians
f  continuous variables were compared using Kruskal–Wallis’
est. Signiﬁcance level was  chosen at 5% (p < 0.05).
The current study was  approved by UFMG Ethics Commit-
ee  (approval ETIC 260-03-EX 01/07).
esults
 total of 2007 infants born to HIV-infected mothers were
ollowed-up and systematically tested for toxoplasmosis in
he ﬁrst year of life. Out of this population, 10 children born
o  nine co-infected mothers were  identiﬁed with congenital
oxoplasmosis. Prenatal information of one of the women who
ave birth in 1991 was  not available in the database. Most
omen  (7/8) were identiﬁed as HIV-infected during pregnancy.
iming  of T. gondii infection could not be determined based
n  the analysis of maternal serologic tests. Two pregnant
omen  (2/7) had clinical manifestations of toxoplasmosis, but
ere not provided speciﬁc treatment because the diagnosis
as  not conﬁrmed upon delivery. One pregnant woman (1/7)4;1 8(6):609–617  611
was  given sulfametoxazol and trimethoprim (SMX–TMP) as
prophylaxis  against pneumocystis during pregnancy, but its
use was  irregular. A great proportion of clinical manifesta-
tions were observed in the cohort/BH: eye and brain damage
affected  87.5% and 70.0% of the children, respectively. As in
the  pregnant women, there was  difﬁculty in diagnosing the
disease  due to lack of speciﬁc IgM and IgA during the ﬁrst
months  of life (Table 1).
In total, the bibliographic review retrieved 17 articles with
22  cases of congenital toxoplasmosis in children of co-infected
mothers. Four articles reported cross-sectional studies. Con-
genital  toxoplasmosis was  rare and associated with maternal
immunosuppression during pregnancy.7 Only four articles
were  written by Brazilian researchers reporting six cases
altogether9,16,20,21 (Table 2).
Comparison  of pregnant women  and children according to
place  of origin (Brazil vs. other countries) points to similar
characteristics. However, only one Brazilian pregnant woman
was  diagnosed in the pre-HAART (Highly Active Antiretrovi-
ral  Therapy) era, which contrasts with the pregnant women
from  other countries (p = 0.002). The group of pregnant women
from  other countries included twice as many  women  with
CD4+ < 200 cells/mm3 than the group of Brazilian women,
but  this difference proved not to be signiﬁcant. Differences
between child mortality rates were found signiﬁcant between
places  of origin (p = 0.003): 80% of the deaths among children
from  other countries, out of which 92% had toxoplasmosis
diagnosed post-mortem (Tables 3 and 4).
Several cases of vertical toxoplasmosis transmission were
observed  among the immunosuppressed pregnant women,
but  this also took place among women with more  than 500
CD4+ cells (Table 4). In the HIV-infected cohort from Belo Hori-
zonte,  the mean absolute CD4+ values were higher than that
in  other settings. This was probably due to the wider variation
on  CD4+ values (36–917 CD4+ cells/mm3) (Table 5).
Discussion
The Belo Horizonte cohort (10 children born to 9 women)
represents the highest number of children with congenital
toxoplasmosis born to HIV and T. gondii co-infected mothers
that  have been reported by a single center. Considering the
total  cases of children with congenital toxoplasmosis born to
co-infected mothers reported in the literature, half of them
were  from Brazil, with the cohort/BH representing approxi-
mately  one-third of the total.
Occurrence of congenital toxoplasmosis in children born
to  HIV and T. gondii co-infected mothers is rare, as shown in
the  cohort/BH and the few cases reported worldwide. The
cohort/BH,  however, points out the need for investigating
T. gondii infection systematically to diagnosis congenital
toxoplasmosis among newborns that have been exposed to
HIV. It also shows that, even in the post-HAART area, children
are  still at risk of acquiring congenital toxoplasmosis, and
it  is pertinent to discuss the best approach to co-infected
pregnant women and their children. In addition, it contributes
to  reinforcing the association between vertical T. gondii trans-
mission  and chronic infection in immunosuppressed women.
Additionally, this two-decade long observational study indi-
cates  that pregnant women transmitted toxoplasmosis to
612  b r a z j i n f e c t d i s . 2 0 1 4;1  8(6):609–617
Table 1 – Frequency distribution of clinical and laboratory characteristics of children with congenital toxoplasmosis and
their HIV/T. gondii co-infected mothers according to the children’s place of origin (Metropolitan Area of Belo Horizonte,
other regions in Brazil, and other countries).
Pregnant women
Case studies cohort/BH Literature cases in Brazil Literature cases worldwide
Frequency % Frequency % Frequency %
Total number of pregnant
women
9  6 15
Pregnant women diagnosed
with  infection during
pregnancy
7/8  87.5 5/5 100.0 10/13 76.9
Pregnant women with CD4+
>500 cells/mm3
1/6 16.6 0/11 9.0 0/9 0.0
CD4+ < 200 cells/mm3 a 2/5 40.0 3/5 60.0 7/9 77.8
Viral
load > 100,000 copies/mLa
2/4 50.0 1/5 20.0 0/3 0.0
Antiretroviral therapy 5/7 71.5 6/6 100.0 4/8 50.0
SMX–TMP therapy 1/7 14.3 0/2 0.0 2/5 40.0
Toxoplasmosis treatment 0/4 0.0 1/5 20.0 2/11 18.2
Clinic manifestations of
toxoplasmosis
2/7  28.5 2/5 40.0 5/12 41.7
IgM+ during pregnancy 1/3 33.3 0/6 0.0 2/10 20.0
Chronic infection 2/2 100.0 5/6 83.3 8/10 80.0
Children
Case studies cohort/BH Literature  cases in Brazil Literature cases worldwide
Frequency % Frequency % Frequency %
Total number of children 10 6 16
Pre-HAART 1/10 10.0 0/6 0.0 11/16 68.75
Term birth 5/9 55.5 3/5 60.0 6/13 46.1
HIV co-infected children 5/9 55.5 3/5 60.0 10/12 83.3
Chorioretinitis 7/8 87.5 4/5 80.0 5/8 62.5
Brain damage 7/10 70.00 2/4 50.0 8/10 80.0
Systemic symptoms of toxoplasmosis 4/4 100.0 2/5 40.0 11/12 91.7
Test for toxoplasmosis in the ﬁrst quarter 8/10 80.0 6/6 100.0 14/16 87.5
Anti-T. gondii IgM/IgA or PCR + at birth 4/10 40.0 6/6 100.0 7/12 58.3
Result through autopsy 0/2 0.0 1/1 100.0 11/12 91.7
Treatmentb 8/10 80.0 5/5 100.0 7/10 70.0
Mortalityc 2/10 20.0 1/4 25.0 12/15 80.0
a The highest viral load value and the lowest CD4+ value were used referring necessarily to a given moment in the pregnancy. The level of 20%
of CD4+ lymphocytes corresponded to an absolute count at 350 cells/mm3.
ovide
f reseb Every treatment for toxoplasmosis was included in the analysis, pr
c Death was considered for those cases reported up to the last day o
their children even when they did not have severe immuno-
suppression or kept absolute CD4+ values within normal
limits.
A  recent study has estimated the prevalence of congeni-
tal  toxoplasmosis at 0.13% in the general population in the
state  of Minas Gerais, one infected child in every 770 live
births.8 Considering this estimate and the number of HIV-
exposed  children followed up in the cohort/BH (n = 2007), the
expected  estimate before this study was  two or three children
with  congenital toxoplasmosis. Therefore, 10 infected chil-
dren,  as identiﬁed in the present study, represent a prevalence
that  is at least three times higher than expected in newborns
of  HIV-uninfected pregnant women. Since the Brazilian envi-
ronment  is favorable to T. gondii infection, HIV infection still
occurs  among mothers in reproductive age, and as congeni-
tal  toxoplasmosis manifests somewhat later in the newborns’d that it was carried out in the ﬁrst year of life.
arch or date of publication.
lives,  these cases might have been underestimated in our
country.
In  the present study we were not able to ascertain the risk
of  toxoplasmosis transmission among co-infected pregnant
women.  The European Collaborative Study has estimated it to
be lower than 4.2%.22 This study, carried out in the pre-HAART
era  1985–1999, included 1058 children born to 981 Euro-
pean  HIV-infected women estimated maternal prevalence of
toxoplasmosis  of 42.6%, based on speciﬁc IgG detection in
infants  tested before their third month of age. They did
not  differentiate acute from chronic T. gondii infection and
reported  that only 18% of the mothers had CD4+ lympho-
3cyte  count below 200 cells/mm at delivery, and 137 children
had  documented HIV perinatal infection. Other international
studies predicted this risk, and the European AIDS surveil-
lance  system has reported toxoplasmosis occurrence in only
b r a z j i n f e c t d i s . 2 0 1 4;1 8(6):609–617  613
Table 2 – Distribution of studies on children with congenital toxoplasmosis born to HIV and T. gondii co-infected mothers,
according to year and place.
Author/place Publication year Type of study Number of cases Results
Cohen-Addad et al.,29 USA 1988 Case report 1 1 co-infected newborn: HIV, T.
gondii,  and CMV
Mitchell et al.,30 USA 1990 Case report 4 3 co-infected newborns: HIV and
T.  gondii; 1 co-infected newborn:
HIV,  T. gondii, and CMV
Medlock et al.,31 USA 1990 Case report 1 1 newborn with toxoplasmosis
Velin et al.,32 France 1991 Case report 1 1 co-infected newborn: HIV and
T.  gondii
O’Donohoe et al.,33 UK 1991  Case report 1  1 co-infected newborn: HIV, T.
gondii,  CMV, and Hep. B
Taccone et al.,34 Italy 1992 Case report 1 1 co-infected newborn: HIV and
T.  gondii
Escribano Subias et al.,35 Spain 1993 Case report 1 1 co-infected newborn: HIV and
T.  gondii
Marty et al.,12 France 1994 Case report 1 1 therapeutic abortion because
of  toxoplasmosis
Minkoff et al.,7 USA 1997 Prospective
cross-sectional study
1a 1 newborn with toxoplasmosis
Marty et al.,10 France 2002 Case report 1 1 fetal death because of
toxoplasmosis
Bachmeyer et al.,11 France 2006 Case report 1 1 newborn with toxoplasmosis
Cruz et al.,16 Brazil 2007 Cross-sectional study 1b 1 newborn with toxoplasmosis
Fernandes et al.,9 Brazil 2009 Case report 1 1 co-infected newborn: HIV and
T.  gondii
Lago et al.,21 Brazil 2009 Prospective
cross-sectional study
1c 1 co-infected newborn: HIV and
T.  gondii
Azevedo et al.,20 Brazil 2010  Cross-sectional study 3d 1 fetal death, 1 newborn with
toxoplasmosis,  1 co-infected
newborn  HIV and T. gondii
Caby et al.,36 France 2010 Case report 1 1 fetal death
Tan et al.,26 Canada 2010 Case report 1 1 co-infected newborn: HIV, T.
gondii,  and CMV
Case studies (cohort/BH), Brazil 2012 Case report 10 5 co-infected newborns: HIV and
T.  gondii
a One case out of 121 HIV-exposed children of mothers with IgG+ during pregnancy.
b One case out of 767 HIV-exposed children monitored from 1996 through 2007.
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5 of the 1762 (1.4%) cases of vertically HIV-infected chil-
ren  reported until late 1994. Nevertheless, it is unknown
hether such cases were  due to congenital or acquired infec-
ion.  Unfortunately, these surveillance systems do not include
eroreverting children born to HIV positive mothers, which
revent  the assessment of the risk of toxoplasmosis trans-
ission  among these co-infected pregnant women.22 Minkoff
t  al.7 indicated a rate of 3.7% of vertical Toxoplasma trans-
ission among HIV-infected women, but transmission could
ake  place in up to 33% of the cases if the women  are severely
mmunocompromised. However, the low prevalence of toxo-
lasmosis  in the sample of pregnant women  (20%) and the
mall  sample size limited the study impact. Although there
re  three prospective studies from Brazil, not enough data are
vailable to determine the risk of transmission.16,20,21
A prospective study was  carried out in the state of
io  Grande do Sul, located in southern Brazil, from 2002
hrough 2005, following up 121 HIV and T. gondii co-infected
regnant women, to investigate the serologic proﬁle of co-
nfected  pregnant women and the risk of transmission ofregnancy.
.
congenital  toxoplasmosis. One child was  identiﬁed with con-
genital  toxoplasmosis, who, according to the authors, was
born  to a mother that had acquired the infection during preg-
nancy  and did not present either high IgG concentration levels
or  IgM antibodies. The study also compared the IgG anti-
T.  gondii concentration level among the co-infected pregnant
women  and 1624 HIV negative pregnant women. The authors
concluded  that high T. gondii-speciﬁc IgG concentration lev-
els  were  much  more  frequent among HIV infected pregnant
women, but without statistical signiﬁcance; high concentra-
tion,  therefore, was  not associated with an increased risk of
mother–fetus  transmission of toxoplasmosis.21 Another study
followed  up 767 HIV-exposed children in the city of Rio de
Janeiro,  Brazil, from 1996 through 2007. Only one child had
congenital  toxoplasmosis, and 74% of the mothers had sero-
logical  evidences of IgG anti-Toxoplasma during pregnancy.16 A
third study, also in Rio de Janeiro, describes three children with
congenital  toxoplasmosis out of the 113 HIV-exposed children.
In  the sample, 70% of the pregnant women had serological (IgG
positive)  evidence of T. gondii infection during pregnancy.20 A
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Table 3 – Frequency distribution of pregnancy characteristics of HIV/T. gondii co-infected mothers of children with
congenital toxoplasmosis, according to the children’s place of origin (Metropolitan Area of Belo Horizonte, other regions
in Brazil, and other countries).
Variable Cases p value
Brazilian Worldwide
Frequency % Frequency %
Total number 15
Exposure  to HIV
Pre-HAART 1/15 6.6 10/15 66.7 0.002
HIV identiﬁcation during pregnancy 12/13 92.3 10/13 76.9 0.593
Antiretroviral therapy 11/13 84.6 4/8 50.0 0.146
SMX–TMP therapy 1/9 11.1 2/5 40.0 0.505
Immune response to HIV
CD4+ < 200 cells/mm3 4/10 40.0 7/9 77.7 0.115
Viral load > 100,000 copies/mLa 3/9 33.3 0/3 0.0 0.509
Monitoring for toxoplasmosis
Eye  damage 1/3 33.3 0/0 0.0 –
Systemic symptoms 4/12 33.3 5/12 41.6 1.000
IgM+ during pregnancy 1/9 11.1 2/10 20.0 1.000
Treatment for toxoplasmosis 1/9 11.1 2/11 18.1 1.000
Chronic infection 7/8 87.5 8/10 80.0 1.000
referra The highest viral load value and the lowest CD4+ value were used 
fourth study, also carried out in Rio de Janeiro (1996–2001),
consisted of a cohort of 227 HIV-infected pregnant women,
and  found a prevalence of chronic T. gondii infection among
71.4%  of them.23,24 Five children of this cohort were infected
with  HIV, but no case of congenital toxoplasmosis was  diag-
nosed.  The women  with CD4+ < 200 cells/mm3 were provided
with  SMX–TMP three times a week during pregnancy.24 This
Table 4 – Comparison between Brazilian and international case
Variable 
Brazil
Frequency 
Total number 16
Birth  conditions
Term birth 8/14 
Exposure to HIV
Pre-HAART era (1995) 1/16 
HIV-co-infected children 8/14 
CD4+ < 200 cells/mm3 0/4 
Toxoplasmosis manifestations
Eye  damage 11/13 
Brain damage 9/14  
Systemic symptoms 6/9 
Monitoring for toxoplasmosis
Tests  in the ﬁrst quarter 14/16 
IgM or IgA or PCR + in the ﬁrst quarter of life 10/16 
Autopsy 1/3 
Outcome
Treatment for toxoplasmosisb 13/15 
Deathc 3/14 
b Every treatment for toxoplasmosis was included in the analysis, provide
c Death was considered for those cases reported up to the last day of reseing necessarily to a given moment in the pregnancy.
prophylactic regimen was used for pneumocystis prevention,
but  may  have contributed to preventing reactivation of latent
toxoplasmosis, which may  have accounted for a rare occur-
rence  of vertical transmission.25Altogether, these data call for caution in interpreting the
estimate  of 4% risk of vertical toxoplasmosis transmission in
co-infected pregnant women  that has been reported in the
s according to children’s characteristics.
Cases p value
ian Worldwide
% Frequency %
57.1 6/13 46.1 0.706
6.25 11/16 68.75 0.001
57.1 10/12 83.3 0.216
0 1/5 20.0 1.000
84.6 5/8 62.5 0.325
64.2 8/10 80.0 0.653
66.6 11/12 91.6 0.272
87.5 14/6 87.5 1.000
62.5 7/12 58.3 1.000
33.3 11/12 91.6 0.081
86.6 7/10 70.0 0.358
21.4 12/15 80.0 0.003
d that it was carried out in the ﬁrst year of life.
arch or date of publication.
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Table 5 – Comparison of the lowest absolute values of T CD4+ lymphocytes (cells/mm3) during the pregnancy of HIV and
T. gondii co-infected women  and their children with congenital toxoplasmosis, according to place of origin.
Place of origin of co-infected
mothers  and children with
congenital  toxoplasmosis
n  Mean SD Median P25 P50 P75
Cohort/BH 5/9 325.60 348.66 208.00 82.50 208.00 627.50
Cases in other regions in Brazil 5/6 197.40 110.83 171.00  100.00 171.00 308.00
Cases in other countries 9/15 152.89 151.84 100.00 42.00 100.00 263.50
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bKruskal–Wallis test – p = 0.437.
iterature, as the population under scrutiny is heterogeneous.
his risk can be higher among co-infected women with
IV  and chronic T. gondii infection when they have severe
mmunosuppression. Another factor that may  affect vertical
ransmission is the use of antimicrobials as a prophylac-
ic  measure against pneumocystis by immunosuppressed
regnant women.11,25
The ﬁnding of just one child born of the cohort/BH in
he  pre-HAART area may  be explained by the developments
t  the specialized outpatient referral center over time: only
ecently  has it introduced standards for reportable cases,
ollow-up protocols, and systematic performance of serologic
ests  among pregnant women at risk. These developments
lso explain the difference between national and interna-
ional  death rates. The systematic study of toxoplasmosis in
ewborns in Minas Gerais allowed for diagnosing the disease
egardless  of evident clinical damage.
Several challenges exist to diagnosing congenital trans-
ission  of the infection building on its clinical markers.
nfortunately, the Lebech et al.14 criteria used to diagnose
oxoplasmosis in pregnant women and children do not include
ases  of immunosuppression. Clinical manifestations that
ight  prompt suspicions of infection are usually absent or
elated;  80–90% are asymptomatic at birth, regardless of the
o-infection.  Tan et al. have reported a case of a co-infected
ewborn that reputedly had negative results for tomography
f  the skull and fundoscopy, and could not be diagnosed with
oxoplasmosis before the 50th day of life. This case under-
cores  the difﬁculty of diagnosing congenital toxoplasmosis
mong HIV-co-infected individuals and the need for repeat-
ng  diagnostic tests and even empiric therapy, because clinical
nd  radiographic abnormalities may  be identiﬁed belatedly
nd  the results may  be negative in the ﬁrst serological tests.26
xplanations for this may  be: intrauterine exposure to the
MX–TMP  used as a prophylaxis by the mother; disappearance
f  anti-T. gondii IgM during fetal life and its non-detection at
irth;  and the possibility of several congenital co-infections
hat  might share overlapping clinical features, such as CMV.
nother  explanation is that simultaneous HIV infection may
ontribute  to failed IgG immunologic response to T. gondii.26
For laboratory diagnosis of toxoplasmosis, increased anti-
ody  concentrations can be found in the cases of reactivations
n  HIV infected individuals, including pregnant women
ith  CD4+ > 200 cells/mm3. In primo-infection, paradoxically,
umoral response may  be reduced against the recently
ntroduced antigens.20 Reinfection by different strains may
ot  lead to speciﬁc IgM seroconversion.11 Avidity of IgG anti-
odies,  if carried out at the beginning of the pregnancy,may  be useful in assessing the risk of vertical transmission,
since they differentiate a recently acquired infection from an
old infection.16 It is not prudent to diagnose fetal infection
through parasite DNA detection in amniotic liquid because
of  the risk of infecting the fetus with HIV during the proce-
dure  on co-infected pregnant women.26 These results pose
difﬁculties in dealing with suspected cases of toxoplasmosis
and implementing treatment measures aimed at the newborn.
Therefore, to increase sensitivity to conﬁrm suspected cases
among  newborns, physicians should perform IgG, IgM, and IgA
speciﬁc tests in the immediate postnatal period. Initial neg-
ative  results should imply repeating the tests. Parasite DNA
tests  through PCR of the children’s blood or cerebro-spinal
ﬂuid sample may  contribute to an accurate diagnosis.
Several authors advise that all infants born to HIV seropos-
itive  mothers should be tested for congenital infections.
Physicians should not miss the opportunity to treat chil-
dren  from their birth or even during their intrauterine life (in
recommended cases).20,26 No consensus exists in relation to
toxoplasmosis prophylaxis during the prenatal period. Some
authors  contend that anti-T. gondii IgG positive women  with
CD4+ < 100 cells/mm3 should be given an antimicrobial pro-
phylaxis  during pregnancy to reduce the risk of transmitting
the  parasite to the fetus. They further argue that this proce-
dure  may  also be appropriate for non-HIV-infected patients
that  are highly immunocompromised for other reasons.7 An
article  by Marty et al. suggests that chemoprophylaxis with
SMX–TMP  associated with antiretroviral treatment should
be  provided to HIV and toxoplasmosis seropositive pregnant
women  when they have CD4+ < 200 cells/mm3 and high viral
load.10,25 Other studies suggest that the risk of maternal–fetal
transmission is not sufﬁciently high to justify routine anti-
toxoplasmosis chemoprophylaxis in HIV-infected pregnant
women,  but they nevertheless emphasize the need for fur-
ther  research on the matter.22 As the risk of maternal–fetal
transmission is not well known, particularly in countries
like  Brazil, which have high rates of T. gondii seropreva-
lence, the current obstetrical tendency of not prescribing
anti-toxoplasmosis chemoprophylaxis to chronically infected
women  is understandable.20
It is recommended that speciﬁc treatment against Toxo-
plasma  be initiated in HIV and toxoplasmosis co-infected
children for one year, after which secondary prophylaxis
should be provided. In Brazil, the recommendation is to hold
back  on secondary chemoprophylaxis until two consecutive
assessments prove that CD4+ lymphocyte is higher than 15%.9
Although the small sample size is a limitation of this study,
it  is important to emphasize that this is a cohort of two
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decades with systematic investigation of toxoplasmosis in
infants  born to HIV infected mothers, which allowed iden-
tiﬁcation  of vertical transmission in HIV infected pregnant
women  with chronic toxoplasmosis. Incompleteness of study
variables  is a common bias encountered in retrospective stud-
ies.  This limitation was  minimized in the present study by the
existence  of standardized clinical forms used for the follow-up
of  both cohorts.
The  authors of this study underscore the importance
of diagnosis and treating toxoplasmosis in the prenatal
period, along with HIV monitoring during the entire preg-
nancy.  Immunodepression, even when mild, may  contribute
to  the transmission of latent infections to the newborn, and
this  could be averted with appropriate treatment. Immuno-
compromised women  should be tested for toxoplasma and
cytomegalovirus infection in multiple occasions throughout
their  pregnancy. Successful cases have shown that adequate
measures preserve the mothers’ health and avoid fetus infec-
tion  in this scenario.23,27,28
Conclusion
To date, the general risk of maternal–fetal transmission of
Toxoplasma  infection is deemed to be low among HIV-infected
women, even when their CD4+ lymphocyte counts are very low
(<200 cells/mL). However, the cohort/BH had a higher number
of  cases of congenital toxoplasmosis than expected among
children  born to co-infected mothers. Despite the discrep-
ancy,  these data should be interpreted with caution, due to
the  heterogeneity of the population under scrutiny, classiﬁca-
tion  biases that hinder association between transmission and
acute  or chronic T. gondii infection, insufﬁcient sample sizes
to  detect cases of the disease, and the paucity of prospective
studies monitoring the mother/child duo.
This risk is also estimated to be low in countries
with a high prevalence of toxoplasmosis, such as Brazil,
and  associated with the mothers’ severe immunodeﬁciency
(CD4+ < 200 cells/mm3) and high viral load. However, the occur-
rence  of the disease among asymptomatic pregnant women
with  latent toxoplasmosis and CD4+ within normal limits
underscores the need for careful monitoring of both mother
and  child in these cases. Further studies are needed to deter-
mine  the effect of chemoprophylaxis on the transmission
rates. The authors recommend that toxoplasmosis tests be
carried  out in all infants born to HIV-seropositive mothers.
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